Evidence map›Paper›PMID 30976847›Full record

ArticleArchives of toxicology2019

The LRP6 functional mutation rs2302685 contributes to individual susceptibility to alcoholic liver injury related to the Wnt/β-catenin-TCF1-CYP2E1 signaling pathway.

Ying Xu, Dan Chen, Xiu-Xian Lin, Qing Zhao, Jing Guo, Li-Jie Chen, Wei Zhang, Jian Xiao, Guang-Hui Lian, Shi-Fang Peng and 5 more

Abstract read
PubMed Publisher
In one paragraph

Article in Archives of toxicology, 2019. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Cited by 10 papers, 1 of them a synthesis that pooled it.

0numbers the graph read from it
0cells of the map it votes in
10citing papers in PubMed, 1 pooled it
2.6field-weighted citation impact, top 10% of its field
1 · What the graph read from it

What it found

Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.

The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.

2 · The registry

The trial behind it

Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.

Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.

3 · Its place in the literature

Who cites it

10 citing papers in PubMed, 1 synthesis or guideline pooled it, 23 citations in OpenAlex.

  1. Pooled it
  2. Article
  3. Review
  4. Article
  5. Article
  6. Article
  7. Article
  8. Article
  9. Review
  10. International journal of biological sciences · 2021
    Article
4 · The record

Corrections and comments

PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.

5 · Who and what money

Authors and funding

15 authors at 3 institutions in 2 countries.

Ying Xu *Department of Clinical Pharmacology, Xiangya Hospital, Central South University, Changsha, 410008, Hunan, China.
Dan Chen *Department of Clinical Pharmacology, Xiangya Hospital, Central South University, Changsha, 410008, Hunan, China.
Xiu-Xian Lin *Department of Clinical Pharmacology, Xiangya Hospital, Central South University, Changsha, 410008, Hunan, China.
Qing ZhaoDepartment of Clinical Pharmacology, Xiangya Hospital, Central South University, Changsha, 410008, Hunan, China.
Jing GuoDepartment of Clinical Pharmacology, Xiangya Hospital, Central South University, Changsha, 410008, Hunan, China.
Li-Jie ChenDepartment of Clinical Pharmacology, Xiangya Hospital, Central South University, Changsha, 410008, Hunan, China.
Wei ZhangDepartment of Clinical Pharmacology, Xiangya Hospital, Central South University, Changsha, 410008, Hunan, China.
Jian XiaoDepartment of Hepatology and Infectious Diseases, Xiangya Hospital, Central South University, Changsha, 410008, Hunan, China.
Guang-Hui LianDepartment of Gastroenterology, Xiangya Hospital, Central South University, Changsha, 410008, Hunan, China.
Shi-Fang PengDepartment of Pharmacy, Xiangya Hospital, Central South University, Changsha, 410008, Hunan, China.
Dong GuoDepartment of Pharmaceutical Sciences, School of Pharmacy, University of Maryland, Baltimore, MD, 21201, USA.
Hong YangDepartment of Pharmaceutical Sciences, School of Pharmacy, University of Maryland, Baltimore, MD, 21201, USA.
Obinna ObianomDepartment of Pharmaceutical Sciences, School of Pharmacy, University of Maryland, Baltimore, MD, 21201, USA.
Yan ShuDepartment of Pharmaceutical Sciences, School of Pharmacy, University of Maryland, Baltimore, MD, 21201, USA.
Yao ChenDepartment of Clinical Pharmacology, Xiangya Hospital, Central South University, Changsha, 410008, Hunan, China. cbohua@csu.edu.cn.
Central South University · CNUniversity of Maryland, Baltimore · USXiangya Hospital Central South University · CN

Funding

the Changsha Science and Technology Plan Kq1602014the National Science and Technology Plan of China 2017ZX09304014the National Scientific Foundation of China 81302850the Natural Science Foundation of Hunan Province 2018JJ2629
6 · The paper itself

Abstract

Low-density lipoprotein receptor-related protein 6 (LRP6) is an important coreceptor in the Wnt/β-catenin upstream signaling pathway. Rs2302685 is a common functional mutation of LRP6 that has been previously associated with reduced alcoholic liver injury among alcoholic liver disease (ALD) patients, and the present research was designed to study the underlying mechanisms of that finding. A total of 107 ALD patients and 138 non-ALD patients were recruited from hospitalized alcoholics in China. Their venous blood samples were collected for DNA extraction and genotyped using Sequenom MassARRAY. We found that the rs2302685 mutation, which impaired the function of LRP6, was present in higher frequency among alcoholics with ALD than those without ALD. We also conducted a mouse model experiment in which LRP6

Indexed as

AdultAgedAnimalsbeta CateninCytochrome P-450 CYP2E1EthanolFemaleGenetic Predisposition to DiseaseHepatitis, AlcoholicHepatocyte Nuclear Factor 1-alphaHumansLiverLiver Function TestsLow Density Lipoprotein Receptor-Related Protein-6MaleMicebeta CateninCytochrome P-450 CYP2E1EthanolHepatocyte Nuclear Factor 1-alphaHNF1A protein, humanLow Density Lipoprotein Receptor-Related Protein-6LRP6 protein, humanLrp6 protein, mouseAlcoholic liver injuryALDCYP2E1LRP6Wnt/β-catenin

Identifiers

PMID30976847
OpenAlexW2938973179

What OpenQuestion holds

Textmetadata
Read underepoch 390

Registered trials

None linked

Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.